Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 3Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Sarcoma, Myeloid 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Arsenic Trioxide 6Tretinoin 5venetoclax 1arsenous acid 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Idarubicin 1Gemtuzumab 1Gadolinium 1Fluorodeoxyglucose F18 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Promyelocytic, Acute × Gemtuzumab × 1 year × Clear all
NCT01409161 2026-05-20

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
151 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡